Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cell therapy Descartes-08 tested in teens with lupus and other autoimmune diseases

NCT ID NCT07089121

Recruiting now Disease control Sponsor: Cartesian Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This early-stage trial is testing Descartes-08, a cell therapy made from modified immune cells, in 50 young people aged 12 and older with four autoimmune diseases: childhood-onset lupus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis. The study has two parts: first, finding the safest dose, then giving that dose weekly for six weeks to see how safe and tolerable it is. The goal is to gather safety data, not yet to prove the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Descartes-08 (a cell therapy using modified immune cells)
What this could lead to
If it works, this could point toward a new treatment option for young people with certain autoimmune diseases that are hard to control with current therapies.
What could go wrong
This is an early Phase 1/2 trial with only 50 participants, so it is primarily testing safety and dosing. It may not show clear benefit, and cell therapies can have serious side effects like infusion reactions or immune overactivation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anti-neutrophil cytoplasmic antibody-associated vasculitis dermatomyositis granulomatosis with polyangiitis juvenile dermatomyositis juvenile myasthenia gravis pediatric systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANCA ASSOCIATED VASCULITIS (AAV) CHILDHOOD-ONSET SYSTEMIC LUPUS ERYTHEMATOUS JUVENILE DERMATOMYOSITIS JUVENILE MYASTHENIA GRAVIS

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Center

    RECRUITING

    Cincinnati, Ohio, 45229, United States

  • H01- Children's National Hospital

    RECRUITING

    Washington D.C., District of Columbia, 20010, United States

  • H03- Washington University School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.